10.57
Avita Medical Inc stock is traded at $10.57, with a volume of 950.27K.
It is up +20.39% in the last 24 hours and up +18.90% over the past month.
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult patients in the US with paediatric clinical trials and expanded indications in soft-tissue reconstruction and vitiligo underway. It is currently in roll-out across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.
See More
Previous Close:
$8.78
Open:
$9.92
24h Volume:
950.27K
Relative Volume:
5.57
Market Cap:
$277.12M
Revenue:
$50.14M
Net Income/Loss:
$-35.38M
P/E Ratio:
-7.55
EPS:
-1.4
Net Cash Flow:
$-39.46M
1W Performance:
+21.77%
1M Performance:
+18.90%
6M Performance:
+17.58%
1Y Performance:
-38.97%
Avita Medical Inc Stock (RCEL) Company Profile
Name
Avita Medical Inc
Sector
Industry
Phone
661-568-1317
Address
28159 AVENUE STANFORD, VALENCIA, CA
Compare RCEL with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
RCEL
Avita Medical Inc
|
10.57 | 277.12M | 50.14M | -35.38M | -39.46M | -1.40 |
![]()
ABT
Abbott Laboratories
|
130.61 | 226.54B | 41.95B | 13.40B | 6.49B | 7.65 |
![]()
BSX
Boston Scientific Corp
|
106.11 | 156.39B | 16.75B | 1.85B | 1.89B | 1.25 |
![]()
SYK
Stryker Corp
|
385.18 | 146.98B | 22.60B | 2.99B | 3.49B | 7.76 |
![]()
MDT
Medtronic Plc
|
92.81 | 119.01B | 33.00B | 4.29B | 5.50B | 3.27 |
![]()
EW
Edwards Lifesciences Corp
|
76.19 | 44.94B | 5.72B | 4.17B | 490.10M | 6.97 |
Avita Medical Inc Stock (RCEL) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Dec-24-24 | Initiated | D. Boral Capital | Buy |
Apr-11-24 | Downgrade | BTIG Research | Buy → Neutral |
Jun-27-23 | Initiated | Cantor Fitzgerald | Overweight |
Mar-02-21 | Initiated | Piper Sandler | Overweight |
Aug-27-20 | Initiated | BofA Securities | Buy |
Apr-21-20 | Initiated | Oppenheimer | Outperform |
Mar-03-20 | Initiated | BTIG Research | Buy |
View All
Avita Medical Inc Stock (RCEL) Latest News
Cantor maintains Avita stock Overweight with $19 target - MSN
AVITA Medical to Host Investor Webinar Briefing - The Manila Times
Inside AVITA Medical's 2024 Performance: CEO & CFO Reveal Growth Strategy - StockTitan
Analyst Expectations For AVITA Medical's Future - Benzinga
AVITA Medical Inc (RCEL) Q4 Earnings: EPS of -$0.44 Misses Estimate, Revenue of $18.4M Falls Short - GuruFocus.com
Avita Medical Reports Wider Q4 Loss Despite Higher Revenue; Shares Up 12% -February 13, 2025 at 10:41 pm EST - Marketscreener.com
AVITA Medical Inc reports results for the quarter ended December 31Earnings Summary - TradingView
AVITA Medical, Inc. SEC 10-K Report - TradingView
AVITA Medical (ASX:AVH) Reports Q4 and FY 2024 Financial Results - The Capital Club
AVITA Medical Reports Fourth Quarter and Full Year 2024 Financial Results - The Manila Times
FDA Approves RECELL GO mini - MPO-mag
Wound Closure Devices Market to See Drastic Growth – Post 2025 | AVITA Medical, ConvaTec, Organogenesis - Newstrail
Trend Tracker for (RCEL) - Stock Traders Daily
AVITA gets FDA clearance for Cohealyx for wound care - MSN
Terry Bromley Chosen to Lead Imbed Biosciences - MPO-mag
FDA Clears AVITA Medical’s Cohealyx Dermal Matrix - MPO-mag
Avita medical director Suzanne Crowe buys $6,390 in stock - MSN
AVITA Medical (NASDAQ:RCEL) adds US$24m to market cap in the past 7 days, though investors from five years ago are still down 81% - Simply Wall St
JPMorgan Chase & Co. Acquires 8,985 Shares of AVITA Medical, Inc. (NASDAQ:RCEL) - Defense World
Avita medical director Suzanne Crowe buys $6,390 in stock By Investing.com - Investing.com UK
(RCEL) Investment Report - Stock Traders Daily
Avita Gets FDA Nod For Device - San Fernando Valley Business Journal
Wound Skin Substitutes Market Forecast to 2030: Chronic Wound Burden Spurs Growth in Advanced Wound Care Technologies - Yahoo Finance
FY2024 EPS Forecast for AVITA Medical Decreased by Analyst - Defense World
Cantor Fitzgerald Expects Weaker Earnings for AVITA Medical - MarketBeat
Brokers Set Expectations for AVITA Medical FY2025 Earnings - Defense World
Cantor Fitzgerald Predicts AVITA Medical FY2025 Earnings - MarketBeat
Burns Pipeline 2024: In-depth Clinical Trials Analysis and Emerging Therapies Report by DelveInsight | MediWound, Kaken Pharma, Kerecis, Medline, Mallinckrodt Pharma, Avita Medical, Vericel Corp - The Globe and Mail
AVITA Medical's shares sink 19% after another forecast cut - MSN
Short Interest in AVITA Medical, Inc. (NASDAQ:RCEL) Rises By 25.9% - MarketBeat
AVITA Medical, Inc. (NASDAQ:RCEL) Holdings Boosted by Barclays PLC - Defense World
Barclays PLC Grows Stock Holdings in AVITA Medical, Inc. (NASDAQ:RCEL) - MarketBeat
(RCEL) Investment Analysis - Stock Traders Daily
Why Avita Medical, Cettire, Domino's Pizza, and Star shares are falling today - MSN
AVITA Medical’s Growth Struggles Amplify Financial Risks (NASDAQ:RCEL) - Seeking Alpha
Investors Burned By AVITA Medical's Sales Miss: I'm Even More Bullish - Seeking Alpha
Health Stock Bleeds After Earnings Downgrade - ShareCafe
AVITA Medical: A Dip Buy As 2025 Looks Bullish With Cohealyx And RECELL GO Mini - Seeking Alpha
Lake Street Capital Issues Pessimistic Forecast for AVITA Medical (NASDAQ:RCEL) Stock Price - Defense World
D. Boral Capital Reiterates Buy Rating for AVITA Medical (NASDAQ:RCEL) - Defense World
ASX shares plunge but remain undervalued - Morningstar.com.au
AVITA Medical, Inc. (RCEL): A Bull Case Theory - Insider Monkey
AVITA Medical's SWOT analysis: regenerative medicine stock faces growth hurdles - Investing.com Australia
AVITA Medical’s SWOT analysis: regenerative medicine stock faces growth hurdles - Investing.com Nigeria
AVITA Medical's SWOT analysis: regenerative medicine stock faces growth hurdles By Investing.com - Investing.com South Africa
Why AVITA Medical, Lovisa, Star, and Westgold shares are sinking today - The Motley Fool Australia
Lake Street cuts Avita Medical stock target, retains buy rating By Investing.com - Investing.com Canada
Avita falls 19% on earnings downgrade - Geelong Advertiser
AVITA Medical Cuts Forecast Again, Shares Tumble - Finimize
AVITA Medical (NASDAQ:RCEL) Price Target Cut to $14.00 by Analysts at Lake Street Capital - MarketBeat
Avita Medical Cuts Annual Sales Forecast On Softer Demand From Hospitals - Benzinga
Avita Medical Inc Stock (RCEL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Avita Medical Inc Stock (RCEL) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
O'Toole David D | CFO |
Dec 05 '24 |
Buy |
12.46 |
975 |
12,152 |
23,734 |
O'Toole David D | CFO |
May 30 '24 |
Buy |
8.90 |
1,000 |
8,900 |
19,734 |
O'Toole David D | CFO |
Feb 28 '24 |
Buy |
17.39 |
1,250 |
21,738 |
18,734 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):